Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 1/20 | 0.62 |
| ▸ | CTSK | P43235 | 1/20 | 0.62 |
| ▸ | OPRD1 | P41143 | 5/20 | 0.56 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.56 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.56 |
| ▸ | GNPAT | O15228 | 1/20 | 0.52 |
| ▸ | REN | P00797 | 1/20 | 0.52 |
| ▸ | LTA4H | P09960 | 2/20 | 0.50 |
| ▸ | MME | P08473 | 1/20 | 0.50 |
| ▸ | ANPEP | P15144 | 1/20 | 0.50 |
| ▸ | ECE1 | P42892 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29434521 | 0.90 | OPRD1 (0.60) | CTSSCTSKOPRD1OPRM1OPRK1 | |
| SCHEMBL29434528 | 0.88 | CTSS (0.60) | CTSSCTSKOPRD1OPRM1OPRK1 | |
| SCHEMBL29613059 | 0.88 | REN (0.55) | CTSSCTSKOPRD1OPRM1OPRK1 | |
| SCHEMBL31388294 | 0.88 | OPRD1 (0.57) | CTSSOPRD1OPRM1OPRK1REN | |
| SCHEMBL28549280 | 0.86 | REN (0.59) | CTSSOPRD1OPRM1OPRK1REN | |
| SCHEMBL28549277 | 0.86 | REN (0.59) | CTSSOPRD1OPRM1OPRK1REN | |
| SCHEMBL11113189 | 0.86 | CTSS (0.63) | CTSSCTSKGNPATLTA4HMME | |
| SCHEMBL9571894 | 0.86 | CTSS (0.63) | CTSSCTSKGNPATLTA4HMME | |
| SCHEMBL9571896 | 0.86 | CTSS (0.63) | CTSSCTSKGNPATLTA4HMME | |
| SCHEMBL22927776 | 0.85 | CTSS (0.67) | CTSSCTSKOPRD1OPRM1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12590273-B2 | Stabilized glycoside hydrolase variants | NOVOZYMES A/S (DK) | 2026-03-31 | — | — | US | disclosed |
| US-12391934-B2 | Stabilized cellulase variants | NOVOZYMES A/S (DK) | 2025-08-19 | — | — | US | disclosed |
| EP-3953463-B1 | STABILIZED GLYCOSIDE HYDROLASE VARIANTS | NOVOZYMES AS (DK) | 2025-08-06 | — | — | EP | disclosed |
| US-20250084394-A1 | STABILIZED CELLULASE VARIANTS | NOVOZYMES A/S (DK) | 2025-03-13 | — | — | US | disclosed |
| US-12129498-B2 | Stabilized endoglucanase variants | NOVOZYMES A/S (DK) | 2024-10-29 | — | — | US | disclosed |
| CN-118530973-A | Stabilized cellulase variants | 诺维信公司 | 2024-08-23 | — | — | CN | disclosed |
| CN-118460512-A | Stabilized cellulase variants | 诺维信公司 | 2024-08-09 | — | — | CN | disclosed |
| CN-112204137-B | Stabilized cellulase variants | 诺维信公司 | 2024-05-14 | — | — | CN | disclosed |
| CN-112272701-B | Stabilized cellulase variants | 诺维信公司 | 2024-05-14 | — | — | CN | disclosed |
| US-20230295591-A1 | STABILIZED CELLULASE VARIANTS | NOVOZYMES A/S (DK) | 2023-09-21 | — | — | US | disclosed |
| US-20230143128-A1 | CARBOHYDRATE BINDING MODULE VARIANTS | NOVOZYMES A/S (DK) | 2023-05-11 | — | — | US | disclosed |
| EP-4133066-A1 | CARBOHYDRATE BINDING MODULE VARIANTS | Novozymes A/S (DK) | 2023-02-15 | — | — | EP | disclosed |
| US-11566239-B2 | Stabilized cellulase variants | NOVOZYMES A/S (DK) | 2023-01-31 | — | — | US | disclosed |
| CN-115210371-A | Carbohydrate binding module variants | 诺维信公司 | 2022-10-18 | — | — | CN | disclosed |
| US-20220186151-A1 | STABILIZED GLYCOSIDE HYDROLASE VARIANTS | NOVOZYMES A/S (DK) | 2022-06-16 | — | — | US | disclosed |
| EP-3953463-A1 | STABILIZED GLYCOSIDE HYDROLASE VARIANTS | Novozymes A/S (DK) | 2022-02-16 | — | — | EP | disclosed |
| EP-0263903-A1 | Method for preparing specific inhibitors of virus-specified proteases | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1988-04-20 | — | — | EP | disclosed |
| EP-0263202-A1 | Inhibition of viral protease activity by peptide halomethyl ketones | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1988-04-13 | — | — | EP | disclosed |
| US-4644055-A | HALOMETHYL KETONE OR METHYL KETONE COVALENTLY LINKED TO PEPTIDE SEQUENCE | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1987-02-17 | — | — | US | disclosed |
| US-4636492-A | ENZYME INHIBITORS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1987-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230143128-A1 | CARBOHYDRATE BINDING MODULE VARIANTS | MGAM, MANBA, MAN2B1 | CTSS 811/4885CTSK 1234/4885OPRD1 4592/4885 |
| US-12590273-B2 | Stabilized glycoside hydrolase variants | IDUA, IDE, TREH | CTSS 900/4885CTSK 1797/4885OPRD1 4560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.